Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Cancer Clinical Trial

Official title:

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03724097
• Other study ID #: OB0052018
• Status: Active, not recruiting
• Start date: October 17, 2017
• Est. completion date: November 1, 2022

Study information

• Verified date: September 2021
• Source: OmicsWay Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer target drugs it allows to rank potential efficacies of target drugs.

Description:

Original computational algorithm Oncobox was developed to determine molecular features of individual tumors. It represents the solution for a personalized selection of target anticancer therapies. The method is based on the analysis of gene expression profile of a cancer sample in comparison with the corresponding normal tissue biosamples in order to select the most effective molecular targets for their inhibition and, accordingly, to identify more effective target drugs for cancer treatment. Histological material obtained from cancer patients during surgery or core-needle biopsy as part of standard treatment will be used for the analysis. Total RNA extracted from the tumor material will be subjected to next-generation sequencing (NGS). By comparing transcriptome profile of the tumor sample with the profiles of the corresponding normal tissue samples the rate of molecular pathways activation/deactivation will be calculated, as well as the case-to-normal ratios for the individual gene products - molecular targets of drugs. Based on these data, each target drug will be assigned with a score reflecting its potential efficacy for each individual tumor treatment. A drug with the score value above 0.1 will be considered potentially effective, a drug with the score value equal to or below 0.1 - as potentially ineffective. Following Oncobox test, 130 target anticancer drugs will be rated according to their predicted effectiveness (see the list of eligible target drugs below). This information will be fully available to a patient and his/her doctor. The doctor will prescribe treatment according to his/her consideration, e.g. based on the standards of care and the patient's life indications. After the appointment of therapy, the patients will be divided naturally into the following three observation groups. The first group will be formed from patients receiving target drugs with the score value above 0,1 as monotherapy or in combination. The second group - patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination. Third group will be formed by patients receiving palliative care. Within this study, these three groups will be compared by response to the therapy according to the results of instrumental studies, by time to progression and by time to progression compared to the previous line of therapy (if any). Additionally, overall survival will be measured in all three groups.

Eligible target drugs:

1. Abemaciclib (LY2835219)

2. Afatinib

3. Aflibercept

4. Alectinib

5. Alemtuzumab

6. Alitretinoin

7. Anastrozole

8. Apalutamide, ARN-509

9. Arsenic trioxide

10. Atezolizumab

11. Avelumab

12. Axitinib

13. Belinostat

14. Bevacizumab

15. Bexarotene

16. Bicalutamide

17. Binimetinib (MEK162)

18. Blinatumomab

19. Bortezomib

20. Bosutinib

21. Brentuximab vedotin

22. Brigatinib

23. Cabazitaxel

24. Cabozantinib

25. Carfilzomib

26. Ceritinib (Zykadia, LDK378)

27. Cetuximab

28. Cobimetinib

29. Crizotinib

30. CYT387 (Momelotinib)

31. Dabrafenib

32. Daratumumab

33. Dasatinib

34. Degarelix

35. Denileukin diftitox (Ontac)

36. Denosumab

37. Docetaxel

38. Dovitinib

39. Durvalumab

40. Elotuzumab

41. Encorafenib

42. Enzalutamide

43. Erlotinib

44. Estramustine

45. Everolimus

46. Exemestane

47. Flavopiridol (Alvociclib)

48. Foretinib

49. Fulvestrant

50. Ganetespib (STA-9090)

51. Gefitinib

52. Goserelin

53. Homoharringtonine (Omacetaxine mepesuccinate)

54. Ibritumomab tiuxetan

55. Ibrutinib

56. Idelalisib

57. Imatinib

58. Inotuzumab ozogamicin

59. Ipilimumab

60. Ixabepilone

61. Ixazomib (MLN9708)

62. Lapatinib

63. Lenalidomide

64. Lenvatinib

65. Letrozole

66. Leuprolide

67. Lomustine

68. Masitinib

69. Medroxyprogesterone acetate (MPA)

70. Megestrol

71. Methyltestosterone

72. Midostaurin

73. Mogamulizumab

74. Moxetumomab pasudotox

75. Necitumumab

76. Nilotinib

77. Nilutamide

78. Nimotuzumab

79. Nintedanib (BIBF 1120)

80. Niraparib

81. Nivolumab (BMS-936558)

82. Obinutuzumab

83. Ofatumumab

84. Olaparib

85. Olaratumab

86. Osimertinib

87. Paclitaxel

88. Palbociclib

89. Panitumumab

90. Panobinostat

91. Pazopanib

92. Pembrolizumab

93. Perifosine

94. Pertuzumab

95. Pomalidomide

96. Ponatinib

97. Ramucirumab (Cyramza)

98. Regorafenib

99. Ribociclib

100. Rigosertib

101. Rituximab

102. Romidepsin

103. Rucaparib

104. Ruxolitinib

105. Selumetinib

106. Siltuximab

107. Sonidegib (LDE225)

108. Sorafenib

109. Sunitinib

110. Tamoxifen

111. Tecemotide (Emepepimut-S, L-BLP25)

112. Temozolomide

113. Temsirolimus

114. Thalidomide

115. Tivantinib

116. Tivozanib

117. Toremifene

118. Trametinib (Mekinst)

119. Trastuzumab

120. Trebananib

121. Vandetanib

122. Veliparib

123. Vemurafenib

124. Venetoclax

125. Vinblastine

126. Vincristine

127. Vindesine

128. Vinorelbine

129. Vismodegib

130. Vorinostat

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: November 1, 2022
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Adults, diagnosed with cancer;

• Age 18 - 80;

• Patients who previously received anticancer treatment within the standard care, patients for whom standard therapy was not indicated or patients refused to receive standard therapy. Patients could receive an unlimited number of treatment lines before this study;

• Available formalin fixed, paraffin-embedded (FFPE) samples of cancer tissue. The material should be confirmed by a certified pathologist, the sample taken for the analysis should contain at least 70% of tumor cells;

• Anticipated survival of at least 3 months since the patient's inclusion in the current investigation;

• Patients who have signed an informed consent.

Exclusion Criteria:

• Anticipated survival of less than 3 months since the patient's inclusion in the current investigation;

• Lack of tumor biopsy material, inability to obtain a new tumor biopsy.

Related Conditions & MeSH terms

• Cancer

Intervention

Other:
• RNA sequencing
Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
• Transcriptome analysis
Analysis of RNA-seq data using the Oncobox algorithm.

Drug:
• target drug with the score above 0,1
target drug with the score above 0,1
• target drug with the score equal or below 0,1
target drug with the score equal or below 0,1
• non-target drug
non-target drug
• palliative care
palliative care

Locations

Country	Name	City	State
Russian Federation	Kaluga Regional Clinical Oncology Center	Kaluga
Russian Federation	"Oncobox" Ltd.	Moscow
Russian Federation	Multidisciplinary medical holding "SM-Clinic"	Moscow
Russian Federation	N.N. Blokhin National Medical Research Center of Oncology	Moscow
Russian Federation	Oncological Clinical Dispensary No. 1 of the Moscow City Health Department	Moscow
Russian Federation	Vitamed LLC	Moscow
United States	OmicsWay Corp.	Walnut	California

Sponsors (7)

Lead Sponsor	Collaborator
OmicsWay Corp.	Kaluga Regional Clinical Oncology Center, Multidisciplinary medical holding SM-Clinic, N.N. Blokhin National Medical Research Center of Oncology, Oncobox Ltd, Oncological Clinical Dispensary No. 1 of the Moscow City Health Department, Vitamed LLC

Countries where clinical trial is conducted

United States,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor response	Tumor response according to the results of instrumental studies	2 years
Primary	Time to progression	Time to progression	2 years
Primary	Time to progression compared to the previous therapy lane	Time to progression compared to the previous therapy lane	2 years
Secondary	Overall survival	Overall survival	2 years